More potent DAPT strategies and oral anticoagulation were tied to worse outcomes and should be avoided, researchers say.

For patients with ACS undergoing DES implantation, de-escalating DAPT to P2Y12 inhibitor monotherapy is associated with lower bleeding risk.

We know from TWILIGHT that ticagrelor monotherapy after an initial 3 months of DAPT also seems to be an acceptable strategy. However, in the THEMIS-PCI trial comparing aspirin/ticagrelor with ...

A deescalation strategy involving switching from ticagrelor to clopidogrel in patients with acute myocardial infarction (AMI) ...

Aspirin for Acute Coronary Syndrome Prior to the Percutaneous Coronary Intervention Era The quest for the most favorable aspirin dose in acute coronary syndromes (ACS) has perplexed investigators ...

The results of PLATO (A Study of Platelet Inhibition and Patient Outcomes) 1 provide a major advance in our understanding of ADP receptor inhibition with the novel agent ticagrelor. When compared ...

meeting in San Diego - showed that giving Brilinta (ticagrelor) alongside aspirin reduced major cardiovascular events in patients who had suffered a heart attack between one and three years ...

Ticagrelor has saved the lives of thousands of heart attack ... Blood clots had only recently been discovered as the cause and aspirin became the standard treatment for preventing further clots.

The filing was based on results from the phase 3 THALES trial, which showed aspirin plus Brilinta 90 mg used twice daily for 30 days resulted in a statistically significant and clinically ...